Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine

European Journal of Pharmacology

Volumn 334, Issue 2-3, 1997, Pages 273-279

  Frey, Kirk ^a,b,c   Kilbourn, Michael ^a   Robinson, Terry ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amphetamine; Dihydrotetrabenazine; Dopamine; Dopamine transporter; Methamphetamine; Neuronal membrane; Vesicular monoamine transporter type 2 (VMAT2); WIN 35,428

Indexed keywords

CARRIER PROTEIN; DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AUTORADIOGRAPHY; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROPEPTIDES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TETRABENAZINE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0030846635     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01152-7     Document Type: Article

References (34)

1. Amara, S.G., Kuhar, M.J., 1993. Neurotransmitter transporters: Recent progress. Annu. Rev. Neurosci. 16, 73-93.
2. 125I]iodoketanserin. Neuroscience 33, 341-349.
3. Eisch, A.J., Gaffney, M., Weihmuller, F.B., O'Dell, S.J., Marshall, J.F., 1992. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598, 321-326.
4. Ellison, G., Eison, M.S., Huberman, H.S., Daniel, F., 1978. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 201, 276-278.
5. Fleckenstein, A.E., Metzger, R.R., Gibb, J.W., Hanson, G.R., 1997. A rapid and reversible change in dopamine transporters induced by methamphetamine. Eur. J. Pharmacol. 323, R9-R10.
6. Hotchkiss, A.J., Gibb, J.W., 1980. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214, 257-262.
7. 11C]dihydrotetrabenazine (DTBZ). Nucl. Med. Biol. 24, 197-199.
8. Kilbourn, M.R., Lee, L., Vander Borght, T.M., Jewett, D., Frey, K.A., 1995. Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur. J. Pharmacol. 278, 249-257.
9. Kish, S.J., Guttman, M., Robitaille, Y., El-Awar, M., Chang, L.-J., Levey, A.I., 1997. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1. Neurol. 48, 1109-1111.
10. Losonczy, M.F., Davidson, M., Davis, K.L, 1987. The dopamine hypothesis of schizophrenia. In: Meltzer, H.Y. (Ed.), Psychopharmacology: A Second Generation of Progress. Raven Press, New York, NY, pp. 745-751.
11. Munson, P.J., Rodbard, D., 1980. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
12. Naudon, L., Leroux-Nicollet, I., Costentin, J., 1994. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter. Neurosci. Lett. 173, 1-4.
13. O'Dell, S.J., Weihmuller, F.B., Marshall, J.F., 1991. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564, 256-260.
14. 3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography. J. Neurosci. 3, 1189-1198.
15. Paxinos, G., Watson, C., 1982. The Rat Brain in Stereotaxic Coordinates. Academic Press, London, UK.
16. Perry, E.K., Marshall, E., Perry, R.H., Irving, D., Smith, C.J., Blessed, G., Fairbairn, A.F., 1990. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimers Dis. Assoc. Disord. 4, 87-95.
17. Pifl, C., Drobny, H., Reither, H., Hornykiewicz, O., Singer, E.A., 1995. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368-373.
18. Polinski, R.J., 1984. Multiple system atrophy. Clinical aspects, pathophysiology and treatment. Neurol. Clin. 2, 487-498.
19. Ritz, M.C., Lamb, R.J., Goldberg, S.R., Kuhar, M.J., 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223.
20. Robinson, T.E., Becker, J.B., 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11, 157-198.
21. Robinson, T.E., Berridge, K.C., 1993. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291.
22. Scatton, B., Javoy-Agid, F., Montfor, J.C., Agid, Y., 1984. Neurochemistry of monoaminergic neurons in Parkinson's disease. In: Usdin, E., Carlsson, A., Dahlstrom, A., Engel, J. (Eds.), Catecholamines, Part C: Neuropharmacology and Central Nervous System - Therapeutic Aspects. Alan R. Liss, New York, NY, pp. 43-52.
23. Seiden, L.S., Ricaurte, G.A., 1987. Neurotoxicity of methamphetamine and related drugs. In: Meltzer, H.Y. (Ed.), Psychopharmacology: A Second Generation of Progress. Raven Press, New York, NY, pp. 359-366.
24. Seiden, L.S., Sabol, K.E., 1993. Amphetamine effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 32, 639-677.
25. Seiden, L.S., Fishman, M.W., Schuster, C.R., 1976. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1, 215-219.
26. 3H]mazindol-labelling of dopamine transporter in rat nucleus accumbens. Eur. J. Pharmacol. 203, 141-144.
27. Singer, H.S., Hahn, I.-H., Moran, T., 1991. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann. Neurol. 30, 558-562.
28. Vandenbergh, D.J., Persico, A.M., Uhl, G.R., 1992. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFPLs. Mol. Brain Res. 15, 161-166.
29. Vander Borght, T., Kilbourn, M., Desmond, T., Kuhl, D., Frey, K., 1995a. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294, 577-583.
30. 3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68, 955-962.
31. Weiner, H.L., Hashim, A., Lajtha, A., Sershen, H., 1989. Chronic L-deprenyl induced up-regulation of the dopamine uptake carrier. Eur. J. Pharmacol. 163, 191-194.
32. 3H-GBR-12,935 are differentially regulated by chronic cocaine self-administration. J. Neurosci. 14, 2966-2979.
33. Wilson, J.M., Kalasinsky, K.S., Levey, A.I., Bergeron, C., Reiber, G., Anthony, R.M., Schmunk, G.A., Shannak, K., Haycock, J.W., Kish, S.J., 1996a. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 2, 699-703.
34. Wilson, J.M., Levey, A.I., Rajput, A., Ang, L., Guttman, M., Shannak, K., Niznik, H.B., Hornykiewicz, O., Pifl, C., Kish, S.J., 1996b. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurol. 47, 718-726.